# US 2013/0295580 A1 · Oral cancer point of care diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295580 A1
- Document ID: US20130295580A1
- Status: Published application
- Kind: A1
- Application number: 13/884,702
- Filed: 2011-11-11
- Published: 2013-11-07
- Earliest claimed: 2010-11-12
- Assignees: William Marsh Rice University; The University of Sheffield; Board of Regents, The University of Texas System
- Inventors: John T. McDevitt; Nicolaos Christodoulides; Pierre N. Floriano; Martin Thornhill; Spencer Redding; Nadarajah Vigneswaran; Craig Murdoch; Paul Speight
- Web page: https://patentgrep.com/patent/US20130295580A1

## CPC

- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/71: for growth factors; for growth regulators
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A point of care diagnostic test, device and disposables for determining a patient risk for oral cancer in the same visit that a sample is collected.

## Claims

### Claim 1

1) A disposable cassette comprising a planar surface having a sample port for applying a patient sample thereto, said sample port fluidly connected to a detection window, said detection window having a membrane for collecting cells, said planar support also having at least one reagent chamber thereon containing reagents wherein said reagent chamber is upstream and fluidly connected to said detection window, said reagents including at least a DNA stain, a cytoplasmic stain, and antibodies specific for at least three biomarkers selected from AVB6 beta6, EGFR, Ki67, Geminin, MCM2, Beta Catenin, and EMMPRIN.

### Claim 2 (depends on 1)

2) The disposable cassette of claim 1, further comprising one wash chamber upstream and fluidly connected to said detection window and membrane.

### Claim 3 (depends on 1)

3) The disposable cassette of claim 1, further comprising at least two buffer chambers upstream and fluidly connected to said of said detection window and membrane, wherein at least one of said buffer chamber is also upstream of said reagent chamber.

### Claim 4 (depends on 1)

4) The disposable cassette of claim 1, further comprising a transparent cover over said detection window.

### Claim 5 (depends on 1)

5) The disposable cassette of claim 1, further comprising a waste chamber fluidly connected and downstream from the detection window and membrane.

### Claim 6 (depends on 1)

6) The disposable cassette of claim 1, further comprising a bubble trap.

### Claim 7 (depends on 1)

7) The disposable cassette of claim 1, further comprising a vent.

### Claim 8

8) A disposable cassette comprising a planar surface having a sample port, a wash chamber, a reagent chamber, a detection window comprising a cell trapping membrane, wherein said sample port is upstream and fluidly connected to said detection window, and wherein said wash chamber and said reagent chamber are upstream and fluidly connected to said detection window, and wherein said waste chamber is downstream and fluidly connected to said detection window, said reagent chamber thereon containing a least a DNA stain, a cytoplasmic stain, and antibodies specific for at least two biomarkers selected from alphaV beta6 (AVB6), Epidermal Growth Factor Receptor (EGFR), Ki67, Geminin, Mini Chromosome Maintenance protein (MCM2), beta catenin, and EMPPRIN.

### Claim 9 (depends on 8)

9) The disposable cassette of claim 8, wherein said detection window further comprises a transparent cover.

### Claim 10 (depends on 8)

10) The disposable cassette of claim 8, wherein said detection window a hinged lid with transparent cover.

### Claim 11 (depends on 8)

11) The disposable cassette of claim 8, wherein said regent chamber comprises dried reagents and a hinged lid.

### Claim 12 (depends on 8)

12) The disposable cassette of claim 8, wherein said reagent chamber comprises dried reagents and a second wash chamber comprising a buffer fluid is upstream and fluidly connected to said reagent chamber.

### Claim 13

13) A test for detecting oral cancer, wherein the test measures:
a) morphological characteristics selected from nuclear area, nuclear diameter, cell area, cell diameter, cytoplasmic area ratio, cell circularity, cell aspect ratio and cell roundness; and
b) at least one biomarker selected from the group consisting of AVB6, EGFR, Ki67, Geminin, MCM2, beta catenin, and EMPPRIN;
c) wherein said test is on performed on a single portable device comprising one or more disposable chips comprising reagents for detecting DNA, cytoplasm, and said at least one biomarker; and
d) wherein the risk of oral cancer is directly proportional to nuclear/cytoplasmic area ratio, cell circularity, cell roundness, EGFR, KI67, Geminin, AVB6, MCM2, beta catenin and EMMPRIN and inversely correlated with cell aspect ratio.

### Claim 14 (depends on 13)

14) The test of claim 13, wherein the biomarker measurement is by immunoassay and the nuclear/cytoplasm ratio and cell shape measurement is by DNA and cytoplasmic stains.

### Claim 15 (depends on 13)

15) The test of claim 13, wherein the measurement of biomarkers is by sandwich immunoassay using capture antibodies and detection antibodies specific for said biomarkers and wherein the detection antibodies are labeled with fluorescent dyes.

### Claim 16 (depends on 13)

16) The test of claim 13, wherein said disposable chip comprises a magnetic bead coupled to an antibody from a surface cancer cell antigen to enrich for cancer cells.

### Claim 17 (depends on 13)

17) The test of claim 13, wherein said test has at least 90% specificity and 90% sensitivity.

### Claim 18 (depends on 13)

18) The test of claim 13, wherein said test has at least 93% specificity and 97% sensitivity.

### Claim 19

19) A method of point of care testing to distinguishing oral cancer from dysplasia and benign lesions, said method comprising:
a) collecting an oral sample from a patient during a patient visit using a rotating brush;
b) applying said sample to a portable device comprising microfluidics, a power source electronics, display means and a removable, disposable chip comprising reagents for detecting DNA, cytoplasm, and at least three biomarkers selected from AVB6, EGFR, Ki67, Geminin, MCM2, Beta Catenin, and EMMPRIN;
c) wherein said device measures nuclear/cytoplasm ratio and cell shape, and said at least three biomarkers in said sample;
d) wherein said device measures computes the risk of oral cancer based on said measurements wherein risk of oral cancer is directly proportional to nuclear/cytoplasmic area ratio, cell roundness, EGFR, KI67, Geminin, AVB6, MCM2, beta catenin ands EMMPRIN and inversely correlated with cell aspect ratio and the risk of benign lesions is the reverse; and
e) wherein said device measures communicates said risk to the patient in the same patient visit as said collecting step a).

### Claim 20 (depends on 19)

20) The method of claim 19, wherein said test has at least 90% specificity and 90% sensitivity.

### Claim 21 (depends on 19)

21) The method of claim 19, wherein said test has at least 93% specificity and 97% sensitivity.
